SBIR Phase II: Manufacturing of Red Blood Cell Membrane-Coated Nanoparticles for detoxification
SBIR Phase II: Manufacturing of Red Blood Cell Membrane-Coated Nanoparticles for detoxification
批准号:
1456104
负责人:
Weiwei Gao
金额:
$75.0万
依托单位:
依托单位国家:
美国
项目类别:
Standard Grant
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-04-01 至 2017-12-31
中文摘要
小企业创新研究(SBIR)二期项目的更广泛影响/商业潜力使红细胞膜涂层纳米颗粒平台的大规模制造成为可能,此前已证明该平台能够吸收和中和多种溶血致病因子,如细菌毒素、动物毒液和自身反应性免疫球蛋白。这种纳米粒子完全由生物兼容和可生物降解的材料组成,并由来自天然红细胞的细胞膜包裹,能够在循环中长时间循环。它们仿生的外表使它们成为诱饵,以清除攻击细胞膜的毒力因子。纳米制剂可用于治疗多种紧迫和未得到满足的医疗需求,包括动物中毒、自身免疫性溶血性疾病和细菌感染。制造工艺的成功开发也在纳米制造和纳米医学开发领域产生了更广泛的影响。建议的项目将使红细胞膜包裹的纳米颗粒能够高效、可靠地大规模生产,并走向临床。为了确保制造的纳米制剂具有最佳的尺寸、均匀性、生物活性和性能,先进的流体、过滤、显微镜和颗粒跟踪技术将被应用于精密纳米颗粒的制备和表征。具体地说,拟议的研究活动将集中在合成具有一致物理化学性质的均匀聚合物纳米颗粒,衍生纯化的和未破坏的红细胞膜,以及在纳米颗粒基质上可靠的细胞膜涂层。生成的纳米颗粒将被彻底检查,以反复改进制备过程。将根据良好的制造规范(GMP)为高质量纳米配方的大规模生产制定优化的制造方案。该项目将促进新型仿生纳米颗粒平台从工作台到床边的过渡,这对解决涉及蛋白质毒素的许多主要疾病具有重要意义。
英文摘要
The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase II project is enabling the large-scale manufacturing of a red blood cell membrane coated nanoparticle platform, which was previously demonstrated to be capable of absorbing and neutralizing a wide array of hemolytic pathogenic factors, such as bacterial toxins, animal venoms, and auto-reactive immunoglobulin. Comprised entirely of biocompatible and biodegradable materials and coated by cell membranes derived from natural red blood cells, the nanoparticles are able to circulate for an extended period of time in the circulation. Their biomimetic exterior allows them to serve as a decoy to scavenge virulence factors that attack cell membranes. The nanoformulation may be applied against multiple pressing and unmet medical needs, including animal envenoming, autoimmune hemolytic diseases, and bacterial infections. Successful development of the manufacturing process also has broader impact in the field of nanofabrication and nanomedicine development. The proposed project will enable the red blood cell membrane-coated nanoparticles to be manufactured efficiently and reliably at a large scale toward clinical translation. To ensure that the manufactured nanoformulations will have the optimal size, uniformity, biological activity, and performance, advanced fluidics, filtration, microscopy, and particle tracking techniques will be applied for precision nanoparticle preparation and characterization. Specifically, the proposed research activity will focus on the synthesis of uniform polymeric nanoparticles with consistent physicochemical properties, derivation of purified and undisrupted red blood cell membranes, and reliable cell membrane coating over the nanoparticle substrates. The resulting nanoparticles will be thoroughly examined to iteratively improve the preparation process. Optimized manufacturing protocol will be developed for large-scale production of high quality nanoformulations following good manufacturing practices (GMP). The project will facilitate the bench-to-bedside transition of the novel biomimetic nanoparticle platform, which has significant implications in addressing the many major diseases involving protein toxins.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
登录
查看更多内容
Baryogenesis, Dark Matter and Nanohertz Gravitational Waves from a Dark
Supercooled Phase Transition
-
批准号:24ZR1429700
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:YUICHIRO NAKAI
-
依托单位:
ATLAS实验探测器Phase 2升级
-
批准号:11961141014
-
项目类别:国际(地区)合作与交流项目
-
资助金额:3350万元
-
批准年份:2019
-
负责人:刘衍文
-
依托单位:
地幔含水相Phase E的温度压力稳定区域与晶体结构研究
-
批准号:41802035
-
项目类别:青年科学基金项目
-
资助金额:12.0万元
-
批准年份:2018
-
负责人:张里
-
依托单位:
基于数字增强干涉的Phase-OTDR高灵敏度定量测量技术研究
-
批准号:61675216
-
项目类别:面上项目
-
资助金额:60.0万元
-
批准年份:2016
-
负责人:叶青
-
依托单位:
基于Phase-type分布的多状态系统可靠性模型研究
-
批准号:71501183
-
项目类别:青年科学基金项目
-
资助金额:17.4万元
-
批准年份:2015
-
负责人:陈童
-
依托单位:
纳米(I-Phase+α-Mg)准共晶的临界半固态形成条件及生长机制
-
批准号:51201142
-
项目类别:青年科学基金项目
-
资助金额:25.0万元
-
批准年份:2012
-
负责人:张英波
-
依托单位:
连续Phase-Type分布数据拟合方法及其应用研究
-
批准号:11101428
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2011
-
负责人:黄卓
-
依托单位:
D-Phase准晶体的电子行为各向异性的研究
-
批准号:19374069
-
项目类别:面上项目
-
资助金额:6.4万元
-
批准年份:1993
-
负责人:张殿琳
-
依托单位: